About half of patients with chronic heart failure have an ejection fraction >40%. Therapy for patients in this group has been challenging until recently; few therapies have been effective in improving clinical outcomes in this population. Recently, data from several clinical trials of SGLT2 inhibitors, mineralocorticoid receptor antagonists (MRA), Angiotensin-receptor neprilysin inhibitors (ARNI), and GLP-1 receptor agonists, however, have offered potential for targeted therapy in this population. Meanwhile, device therapy continues to evolve for this group.

In this interview, Clyde W. Yancy, MD, MSc, MACC, and Akshay S. Desai, MD, MPH, discuss How to Manage Heart Failure With Preserved Ejection Fraction: Practical Guidance for Clinicians.

Related References:

1. Desai, A. S., Lam, C. S. P., McMurray, J. J. V., & Redfield, M. M. (2023). How to Manage Heart Failure With Preserved Ejection Fraction: Practical Guidance for Clinicians. JACC. Heart failure, 11(6), 619–636. https://doi.org/10.1016/j.jchf.2023.03.011
2. Kittleson, M. M., Panjrath, G. S., Amancherla, K., Davis, L. L., Deswal, A., Dixon, D. L., Januzzi, J. L., Jr, & Yancy, C. W. (2023). 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology, 81(18), 1835–1878. https://doi.org/10.1016/j.jacc.2023.03.393